Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2021-02-19 Capital/Financing Update
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience AS: NOK 300 million Private Placement successfully placed
Capital/Financing Update Classification · 98% confidence The document explicitly announces the successful placement of a NOK 300 million Private Placement, detailing the allocation of new shares, the subscription price, and the use of proceeds. This activity directly relates to fundraising, financing, and capital structure changes. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions an upcoming AGM resolution is required to finalize the issuance, the core subject is the successful completion of the financing event itself, not the AGM materials or the final capital change announcement.
2021-02-19 English
Arctic Bioscience announces private placement and intention to list on Euronext Growth Oslo
Capital/Financing Update Classification · 98% confidence The document is an announcement by Arctic Bioscience regarding a 'private placement' to raise NOK 250 million and its 'intention to list on Euronext Growth Oslo'. This clearly describes a fundraising and capital structure event. The key terms are 'private placement', 'raising gross proceeds', 'new share issue', and 'admission to trading'. This aligns directly with the definition of Capital/Financing Update (CAP). It is not a full annual report (10-K), an earnings release (ER), or a simple dividend notice (DIV). Since it is a detailed announcement about the financing terms, it is the primary event, not just a report publication announcement (RPA).
2021-02-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.